Evaluation of research activities and research needs to increase the impact and applicability of alternative testing strategies in risk assessment practice

Regulatory Toxicology and Pharmacology

Volumn 61, Issue 1, 2011, Pages 105-114

  Punt, Ans ^a,b   Schiffelers, Marie Jeanne W A ^c   Jean Horbach, G ^d   van de Sandt, Johannes J M ^e   Groothuis, Geny M M ^f   Rietjens, Ivonne M C M ^b   Blaauboer, Bas J ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b WAGENINGEN UNIVERSITY   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d MSD   (Netherlands)

^e TNO   (Netherlands)

^f UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Alternatives to animal testing; Genomics; In vitro testing; PBK modeling; QSAR; Reduction replacement refinement; Risk assessment; Stem cells; Three R's

Indexed keywords

ANIMAL TESTING ALTERNATIVE; ARTICLE; CARCINOGENICITY; CLINICAL EVALUATION; CLINICAL PRACTICE; CLINICAL RESEARCH; CONCENTRATION (PARAMETERS); ENVIRONMENTAL IMPACT ASSESSMENT; HEALTH SURVEY; HUMAN; IN VITRO STUDY; MATHEMATICAL MODEL; NEEDS ASSESSMENT; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REPRODUCTIVE TOXICITY; RISK ASSESSMENT; TOXICITY TESTING;

ANIMAL TESTING ALTERNATIVES; ANIMALS; DATABASES, FACTUAL; ENDPOINT DETERMINATION; HUMANS; MODELS, BIOLOGICAL; RESEARCH DESIGN; RISK ASSESSMENT;

ANIMALIA;

EID: 80052417259     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2011.06.007     Document Type: Article

References (68)

1. Al-Subeihi A.A., Spenkelink B., Rachmawati N., Boersma M.G., Punt A., Vervoort J., van Bladeren P.J., Rietjens I.M.C.M. Physiologically based biokinetic model of bioactivation and detoxification of the alkenylbenzene methyleugenol in rat. Toxicol. In Vitro 2011, 25:267-285.
2. Andersen M.E., Krewski D. Toxicity testing in the 21st century: bringing the vision to life. Toxicol. Sci. 2009, 107:324-330.
3. Balls M., Bogni A., Bremer S., Casati S., Coecke S., Eskes C., Prieto P., Sabbioni E., Worth A., Zuang V., Barratt M., Blaauboer B.J., Botham P., Combes R., Doehmer J., Fentem J., Liebsch M., Spielmann H. Alternative (non-animal) methods for chemicals testing: current status and future prospects. Altern. Lab. Anim. 2002, 30(1). i-vi+1-125.
4. Barratt M.D. Integration of QSAR and in vitro toxicology. Environ. Health Perspect. 1998, 106(2):459-465.
5. Blaauboer B.J., Andersen M.E. The need for a new toxicity testing and risk analysis paradigm to implement REACH or any other large scale testing initiative. Arch. Toxicol. 2007, 81:385-387.
6. Blaauboer B.J. The contribution of in vitro toxicity data in hazard and risk assessment: current limitations and future perspectives. Toxicol. Lett. 2008, 180:81-84.
7. Blaauboer B.J. Biokinetic modeling and in vitro-in vivo extrapolations. J. Toxicol. Environ. Health B Crit. Rev. 2010, 13:242-252.
8. Bouvier d'Yvoire M., Prieto P., Blaauboer B.J., Bois F.Y., Boobis A., Brochot C., Coecke S., Freidig A., Gundert-Remy U., Hartung T., Jacobs M.N., Lave T., Leahy D.E., Lennernas H., Loizou G.D., Meek B., Pease C., Rowland M., Spendiff M., Yang J., Zeilmaker M. Physiologically-based kinetic modelling (PBK modelling): meeting the 3Rs agenda. The report and recommendations of ECVAM workshop 63. Altern. Lab. Anim. 2007, 35:661-671.
9. Boverhof D.R., Zacharewski T.R. Toxicogenomics in risk assessment: applications and needs. Toxicol. Sci. 2006, 89:352-360.
10. Brown R.P., Delp M.D., Lindstedt S.L., Rhomberg L.R., Beliles R.P. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health 1997, 13:407-484.
11. Clewell R.A., Clewell H.J. Development and specification of physiologically based pharmacokinetic models for use in risk assessment. Regul. Toxicol. Pharmacol. 2008, 50:129-143.
12. Cnubben N.H.P., Peelen S., Borst J.W., Vervoort J., Veeger C., Rietjens I.M.C.M. Molecular orbital-based quantitative structure-activity relationship for the cytochrome P450-catalyzed 4-hydroxylation of halogenated anilines. Chem. Res. Toxicol. 1994, 7:590-598.
13. Coecke S., Ahr H., Blaauboer B.J., Bremer S., Casati S., Castell J., Combes R., Corvi R., Crespi C.L., Cunningham M.L., Elaut G., Eletti B., Freidig A., Gennari A., Ghersi-Egea J.-F., Guillouzo A., Hartung T., Hoet P., Ingelman-Sundberg M., Munn S., Janssens W., Ladstetter B., Leahy D., Long A., Meneguz A., Monshouwer M., Morath S., Nagelkerke F., Pelkonen O., Ponti J., Prieto P., Richert L., Sabbioni E., Schaack B., Steiling W., Testai E., Vericat J.-A., Worth A. Metabolism: a bottleneck in in vitro toxicological test development. The report and recommendations of ECVAM workshop 54. Altern. Lab. Anim. 2006, 34:49-84.
14. Combes R., Grindon C., Cronin M.T., Roberts D.W., Garrod J.F. Integrated decision-tree testing strategies for mutagenicity and carcinogenicity with respect to the requirements of the EU REACH legislation. Altern. Lab. Anim. 2008, 36(1):43-63.
15. Creton S., Dewhurst I.C., Earl L.K., Gehen S.C., Guest R.L., Hotchkiss J.A., Indans I., Woolhiser M.R., Billington R. Acute toxicity testing of chemicals - Opportunities to avoid redundant testing and use alternative approaches. Crit. Rev. Toxicol. 2010, 40:50-83.
16. Cronin M.T., Dearden J.C., Walker J.D., Worth A.P. Quantitative structure-activity relationships for human health effects: commonalities with other endpoints. Environ. Toxicol. Chem. 2003, 22:1829-1843.
17. Cronin M.T., Garrod J.F., Balls M. Development of integrated testing strategies for REACH: motivation, background and introduction. Preface. Altern. Lab. Anim. 2008, 36(1):i-iii.
18. Dearden J.C. In silico prediction of drug toxicity. J. Comput. Aided Mol. Des. 2003, 17:119-127.
19. DeJongh J., Verhaar H.J., Hermens J.L. A quantitative property-property relationship (QPPR) approach to estimate in vitro tissue-blood partition coefficients of organic chemicals in rats and humans. Arch. Toxicol. 1997, 72:17-25.
20. DeJongh J., Nordin-Andersson M., Ploeger B.A., Forsby A. Estimation of systemic toxicity of acrylamide by integration of in vitro toxicity data with kinetic simulations. Toxicol. Appl. Pharmacol. 1999, 158:261-268.
21. EC, 2003. Directive 2003/15/EC of the European parliament and of the council of 27 February 2003 amending council directive 76/768/EEC on the approximation of the laws of the member states relating to cosmetic products. Official Journal L066, 26-35, 11 March 2003.
22. EC, 2007. Corrigendum to Regulation (EC) No. 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorization and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No. 793/93 and Commission Regulation (EC) No. 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC (OJ L396, 30.12.2006). Off. J. Eur. Union, L 136, 50, 2007.
23. Eisenbrand G., Pool-Zobel B., Baker V., Balls M., Blaauboer B.J., Boobis A., Carere A., Kevekordes S., Lhuguenot J.C., Pieters R., Kleiner J. Methods of in vitro toxicology. Food Chem. Toxicol. 2002, 40:193-236.
24. EFSA Guidance of the scientific committee on a request from EFSA on the use of the benchmark dose approach in risk assessment. EFSA J. 2009, 1150:1-72.
25. EPA The use of the benchmark dose approach in health risk assessment. EPA/630/R-94/007 1995, Risk Assessment Forum, Washington, DC.
26. EPA, 2004. Potential implications of Genomics for Regulatory and Risk Assessment Applications at EPA, p. 70. Science Policy Council: U.S. Environmental Protection Agency. http://www.epa.gov/osa/genomics.htm.
27. Forsby A., Blaauboer B.J. Integration of in vitro neurotoxicity data with biokinetic modelling for the estimation of in vivo neurotoxicity. Hum. Exp. Toxicol. 2007, 26:333-338.
28. Foxenberg R.J., Ellison C.A., Knaak J.B., Ma C., Olson J.R. Cytochrome P450-specific human PBPK/PD models for the organophosphorus pesticides: chlorpyrifos and parathion. Toxicology 2011, 285:57-66.
29. Genschow E., Spielmann H., Scholz G., Seiler A., Brown N., Piersma A., Brady M., Clemann N., Huuskonen H., Paillard F., Bremer S., Becker K. The ECVAM international validation study on in vitro embryotoxicity tests: results of the definitive phase and evaluation of prediction models. European centre for the validation of alternative methods. Altern. Lab. Anim. 2002, 30:151-176.
30. Grindon C., Combes R., Cronin M.T., Roberts D.W., Garrod J.F. Integrated testing strategies for use with respect to the requirements of the EU REACH legislation. Altern. Lab. Anim. 2008, 36(1):7-27.
31. Grindon C., Combes R., Cronin M.T., Roberts D.W., Garrod J.F. Integrated decision-tree testing strategies for developmental and reproductive toxicity with respect to the requirements of the EU REACH legislation. Altern. Lab. Anim. 2008, 36(1):123-138.
32. Gubbels-van Hal W.M., Blaauboer B.J., Barentsen H.M., Hoitink M.A., Meerts I.A., van der Hoeven J.C. An alternative approach for the safety evaluation of new and existing chemicals, an exercise in integrated testing. Regul. Toxicol. Pharmacol. 2005, 42:284-295.
33. Hartung T. From alternative methods to a new toxicology. Eur. J. Pharm. Biopharm. 2011, 77:338-349.
34. Health Council of the Netherlands, 2001. Toxicity testing: a more efficient approach. The Hague: Health Council of the Netherlands. Co.
35. Kamgang E., Peyret T., Krishnan K. An integrated QSPR-PBPK modelling approach for in vitro-in vivo extrapolation of pharmacokinetics in rats. Sar and Qsar in Environ. Res. 2008, 19:669-680.
36. Krewski D., Westphal M., Al-Zoughool M., Croteau M.C., Andersen M.E. New directions in toxicity testing. Annu. Rev. Public Health 2011, 32:161-178.
37. Lewis D.F., Ioannides C., Parke D.V. A quantitative structure-activity relationship study on a series of 10 para-substituted toluenes binding to cytochrome P4502B4 (CYP2B4), and their hydroxylation rates. Biochem. Pharmacol. 1995, 50:619-625.
38. Lipscomb J.C., Poet T.S. In vitro measurements of metabolism for application in pharmacokinetic modeling. Pharmacol. Ther. 2008, 118:82-103.
39. Lilienblum W., Dekant W., Foth H., Gebel T., Hengstler J.G., Kahl R., Kramer P.J., Schweinfurth H., Wollin K.M. Alternative methods to safety studies in experimental animals: role in the risk assessment of chemicals under the new European Chemicals Legislation (REACH). Arch. Toxicol. 2008, 82:211-236.
40. Louisse J., de Jong E., van de Sandt J.J., Blaauboer B.J., Woutersen R.A., Piersma A.H., Rietjens I.M.C.M., Verwei M. The use of in vitro toxicity data and physiologically based kinetic modeling to predict dose-response curves for in vivo developmental toxicity of glycol ethers in rat and man. Toxicol. Sci. 2010, 118:470-484.
41. Martati E., Boersma M.G., Spenkelink A., Khadka D.B., Punt A., Vervoort J., van Bladeren P.J., Rietjens I.M.C.M. Physiologically Based Biokinetic (PBBK) Model for Safrole Bioactivation and Detoxification in Rats. Chem. Res. Toxicol. 2011, 24:818-834.
42. Marx-Stoelting P., Adriaens E., Ahr H.J., Bremer S., Garthoff B., Gelbke H.P., Piersma A., Pellizzer C., Reuter U., Rogiers V., Schenk B., Schwengberg S., Seiler A., Spielmann H., Steemans M., Stedman D.B., Vanparys P., Vericat J.A., Verwei M., van der Water F., Weimer M., Schwarz M. A review of the implementation of the embryonic stem cell test (EST). The report and recommendations of an ECVAM/ReProTect workshop. Altern. Lab. Anim. 2009, 37:313-328.
43. McMaster S.B. Developmental toxicity, reproductive toxicity, and neurotoxicity as regulatory endpoints. Toxicol. Lett. 1993, 68:225-230.
44. Mikheev M.I. Toward WHO-recommended occupational exposure limits. Toxicol. Lett. 1995, 77:183-187.
45. Toxicity Testing in the Twenty First Century: A Vision and a Strategy 2007, National Academy of Science (NAS), National Academy Press, Washington, DC.
46. Oberemm A., Onyon L., Gundert-Remy U. How can toxicogenomics inform risk assessment?. Toxicol. Appl. Pharmacol. 2005, 207:592-598.
47. Paini A., Punt A., Viton F., Scholz G., Delatour T., Marin-Kuan M., Schilter B., van Bladeren P.J., Rietjens I.M.C.M. A physiologically based biodynamic (PBBD) model for estragole DNA binding in rat liver based on in vitro kinetic data and estragole DNA adduct formation in primary hepatocytes. Toxicol. Appl. Pharmacol. 2010, 245:57-66.
48. Pelekis M., Emond C. Physiological modeling and derivation of the rat to human toxicokinetic uncertainty factor for the carbamate pesticide aldicarb. Environ. Toxicol. Pharmacol. 2009, 28:179-191.
49. Poulin P., Theil F.P. A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J. Pharm. Sci. 2000, 89:16-35.
50. Punt A., Freidig A.P., Delatour T., Scholz G., Boersma M.G., Schilter B., van Bladeren P.J., Rietjens I.M.C.M. A physiologically based biokinetic (PBBK) model for estragole bioactivation and detoxification in rat. Toxicol. Appl. Pharmacol. 2008, 231:248-259.
51. Punt A., Paini A., Boersma M.G., Freidig A.P., Delatour T., Scholz G., Schilter B., van Bladeren P.J., Rietjens I.M.C.M. Use of physiologically based biokinetic (PBBK) modeling to study estragole bioactivation and detoxification in humans as compared with male rats. Toxicol. Sci. 2009, 110:255-269.
52. Punt A., Jeurissen S.M., Boersma M.G., Delatour T., Scholz G., Schilter B., van Bladeren P.J., Rietjens I.M.C.M. Evaluation of human interindividual variation in bioactivation of estragole using physiologically based biokinetic modeling. Toxicol. Sci. 2009, 113:337-348.
53. Rietjens I.M.C.M., Soffers A.E., Hooiveld G.J., Veeger C., Vervoort J. Quantitative structure-activity relationships based on computer calculated parameters for the overall rate of glutathione S-transferase catalyzed conjugation of a series of fluoronitrobenzenes. Chem. Res. Toxicol. 1995, 8:481-488.
54. Rietjens I.M.C.M., Boersma M.G., Zaleska M., Punt A. Differences in simulated liver concentrations of toxic coumarin metabolites in rats and different human populations evaluated through physiologically based biokinetic (PBBK) modeling. Toxicol. In Vitro 2008, 22:1890-1901.
55. Rietjens I.M.C.M., Punt A., Schilter B., Scholz G., Delatour T., van Bladeren P.J. In silico methods for physiologically based biokinetic models describing bioactivation and detoxification of coumarin and estragole: implications for risk assessment. Mol. Nutr. Food Res. 2010, 54:195-207.
56. Rietjens I.M.C.M., Louisse J., Punt A. Tutorial on physiologically based kinetic modeling in molecular nutrition and food research. Mol. Nutr. Food Res. 2011, 55:941-956.
57. Russell W.M.S., Burch R.L. The Principles of Humane Experimental Technique 1959, Methuen, London.
58. Simmons P.T., Portier C.J. Toxicogenomics: the new frontier in risk analysis. Carcinogenesis 2002, 23:903-905.
59. Soffers A.E., Ploemen J.H., Moonen M.J., Wobbes T., van Ommen B., Vervoort J., van Bladeren P.J., Rietjens I.M.C.M. Regioselectivity and quantitative structure-activity relationships for the conjugation of a series of fluoronitrobenzenes by purified glutathione S-transferase enzymes from rat and man. Chem. Res. Toxicol. 1996, 9:638-646.
60. Spielmann H., Pohl I., Döring B., Liebsch M., Moldenhauer F. The embryonic stem cell test (EST), an in vitro embryotoxicity test using two permanent mouse cell lines: 3T3 fibroblasts and embryonic stem cells. In Vitro Toxicol. 1997, 10:119-127.
61. Stephens M.L. An animal protection perspective on 21st century toxicology. J. Toxicol. Environ. Health B Crit. Rev. 2010, 13:291-298.
62. Takano R., Murayama N., Horiuchi K., Kitajima M., Kumamoto M., Shono F., Yamazaki H. Blood concentrations of acrylonitrile in humans after oral administration extrapolated from in vivo rat pharmacokinetics, in vitro human metabolism, and physiologically based pharmacokinetic modeling. Reg. Toxicol. Pharmacol. 2010, 58:252-258.
63. Tyrakowska B., Cnubben N.H., Soffers A.E., Wobbes T., Rietjens I.M.C.M. Comparative MO-QSAR studies in various species including man. Chem. Biol. Interact. 1996, 100:187-201.
64. Van der Jagt K., Munn S., Tørsløv J., de Bruijn J. Alternative approaches can reduce the use of test animals under REACH. Addendum to the report ''Assessment of additional testing needs under REACH. Effects of (Q)SARs, risk based testing and voluntary industry initiatives" Report EUR 21405 2004, European Commission, Joint Research Centre, Ispra, Italy.
65. Van de Kerkhof E.G., de Graaf I.A., Groothuis G.M. In vitro methods to study intestinal drug metabolism. Curr. Drug Metab. 2007, 8:658-675.
66. Vanhaecke T., Snykers S., Rogiers V., Garthoff B., Castell J.V., Hengstler J.G. EU research activities in alternative testing strategies: current status and future perspectives. Arch. Toxicol. 2009, 83:1037-1042.
67. Verwei M., van Burgsteden J.A., Krul C.A., van de Sandt J.J., Freidig A.P. Prediction of in vivo embryotoxic effect levels with a combination of in vitro studies and PBPK modelling. Toxicol. Lett. 2006, 165:79-87.
68. Yamazaki H., Horiuchi K., Takano R., Nagano T., Shimizu M., Kitajima M., Murayama N., Shono F. Human blood concentrations of cotinine, a biomonitoring marker for tobacco smoke, extrapolated from nicotine metabolism in rats and humans and physiologically based pharmacokinetic modeling. Int. J. Environ. Res. Public Health 2010, 7:3406-3421.